ReviewInternational journal of nanomedicine2026
Nanoparticles in the Treatment of Renal Fibrosis.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Translational advances in diabetic nephropathy management: integrating nanoformulation-based drug delivery systems.Frontiers in medical technology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal fibrosis represents a key pathological hallmark of chronic kidney disease (CKD), a prevalent condition worldwide that currently lacks effective therapies. Nanotechnology offers transformative potential for renal fibrosis treatments. Engineered nanoparticles (NPs), with tunable physicochemical properties such as size, surface charge, and shape, enable targeted and controlled drug delivery. Furthermore, active targeting strategies can increase nanoparticle uptake by specific cell types or structures in kidneys. Although nanomedicine-based strategies for renal fibrosis remain at an early, predominantly preclinical stage, accumulating evidence from experimental models suggests substantial potential for improving therapeutic precision and efficacy in fibrotic kidney disease. This review integrates recent insights into the pathogenesis of renal fibrosis, NP design strategies, along with advances in NP-based therapeutics, highlighting nanomedicine as a promising approach for precise and effective intervention in CKD-associated renal fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.